Evidence map›Paper›PMID 40395973›Full record

ArticleJAC-antimicrobial resistance2025

Pitt candidaemia score as an assessment tool for mortality in patients with candidaemia caused by

Takashi Ueda, Hiroshi Kakeya, Koichiro Yoshida, Akihiro Hisato, Akira Ukimura, Taku Ogawa, Kazuhiko Nakajima, Kosuke Iijima, Miki Nagao, Yasuhiro Tsuchido and 17 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Journal of fungi (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Takashi UedaDepartment of Infection Prevention and Control, Hyogo Medical University Hospital, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.ORCID https://orcid.org/0000-0002-5176-9050
Hiroshi KakeyaDepartment of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Koichiro YoshidaDivision of Infection Control and Prevention, Department of Medical Safety Management, Kindai University Hospital, Osaka, Japan.
Akihiro HisatoDivision of Infection Control and Prevention, Department of Medical Safety Management, Kindai University Hospital, Osaka, Japan.
Akira UkimuraDivision of Infection Control and Prevention, Medical Safety Management Office, Hirakata City Hospital, Osaka, Japan.
Taku OgawaInfection Control Center, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Kazuhiko NakajimaDepartment of Infection Prevention and Control, Hyogo Medical University Hospital, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
Kosuke IijimaDepartment of Clinical Technology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Miki NagaoDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasuhiro TsuchidoDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hideki KawamuraDepartment of Infection Control and Prevention, Kagoshima University Hospital, Kagoshima, Japan.
Akari ShigemiDepartment of Pharmacy, Kagoshima University Hospital, Kagoshima, Japan.
Muneki HotomiDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Masamitsu KonoDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Kei KasaharaDepartment of Infectious Diseases, Nara Medical University, Nara, Japan.
Natsuko ImakitaDepartment of Infectious Diseases, Nara Medical University, Nara, Japan.
Yukihiro KanekoDepartment of Bacteriology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan.
Makoto NikiDepartment of Infection Control and Prevention, Osaka Metropolitan University Hospital, Osaka, Japan.
Koichi YamadaDepartment of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Shigeki KakunoDepartment of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Taiga MiyazakiDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Makoto SumiyoshiDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Yasushi MurakamiDepartment of Respiratory Medicine, Tokoname City Hospital, Tokoname, Japan.
Miki DoiDepartment of Clinical Technology, Tokoname City Hospital, Tokoname, Japan.
Mutsunobu YoshiokaDepartment of Pharmacy, Takarazuka City Hospital, Takarazuka, Japan.
Yoshitsugu MiyazakiDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
Yoshio TakesueDepartment of Infection Prevention and Control, Hyogo Medical University Hospital, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A bedside scoring system to assess the severity of disease is lacking for candidaemia. The Pitt candidaemia score (PCS) was evaluated for its association with mortality. Methods: The PCS consists of five components, namely dialysis, hypotension, mechanical ventilation, cardiac arrest and mental status. Patients were classified into four categories according to their PCS. The correlation between PCS category at blood culture collection and 30 day mortality was studied individually for five Results: Leading rates of mortality were observed in Conclusions: The mortality rate was well stratified by the PCS, and the PCS affected the selection of antifungals. A future prospective study is required for the PCS in guiding therapy for candidaemia.

Identifiers

PMID40395973
PMCPMC12090051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.